Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects

Two open-label, randomized, two-period crossover studies were conducted to investigate the pharmacokinetic (PK) properties, safety, and bioequivalence of the test formulation (KD4004), a new fixed-dose combination (FDC) formulation of dapagliflozin and metformin extended release (XR) tablets, relative to the reference formulation (10 mg dapagliflozin/1,000 mg metformin XR FDC tablet) in healthy subjects under fasting (Part A) and fed (Part B) conditions. After giving the dose, serial blood samples were collected for a period of 48 hours. Primary PK parameters (AUC0-t and Cmax) were used to assess bioequivalence between two dapagliflozin/metformin XR (10/1,000 mg) FDC formulations under fed and fasting conditions. Safety and tolerability were also evaluated. Part A and Part B were completed by 32 and 37 subjects, respectively. Bioequivalence of the two FDC formulations of dapagliflozin and metformin XR tablets was established in both the fasted and the fed conditions as the 90% confidence interval of the ratios of adjusted geometric means for AUC0-t and Cmax were contained within the predefined range of 0.800–1.250 bioequivalence criteria. Single-dose administration of dapagliflozin and metformin XR was safe and well tolerated as the two FDC formulations. In conclusion, both FDC formulations of dapagliflozin and metformin XR tablets were bioequivalent in fed and fasted subjects. All treatments were well tolerated. Trial Registration Clinical Research Information Service Identifier: KCT0004026

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  Longhua Zhou,et al.  Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome , 2021, Scientific Reports.

[3]  T. Nair,et al.  Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel , 2020, Journal of family medicine and primary care.

[4]  Jennifer M. Trujillo,et al.  Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline , 2020, Annals of Internal Medicine.

[5]  D. Boulton,et al.  Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. , 2019, Clinical therapeutics.

[6]  A. Pancholia.  Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus , 2018, Indian heart journal.

[7]  D. Boulton,et al.  Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. , 2018, Clinical therapeutics.

[8]  Damodharan Narayanasamy,et al.  Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review , 2017, Current therapeutic research, clinical and experimental.

[9]  S. Griffen,et al.  Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. , 2015, Clinical therapeutics.

[10]  R. Henry,et al.  Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial , 2012, International journal of clinical practice.

[11]  F. LaCreta,et al.  Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects , 2011, Diabetes, obesity & metabolism.

[12]  S. Griffen,et al.  Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects , 2011, Diabetes, obesity & metabolism.

[13]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[14]  Enrique Morales,et al.  Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes , 2008, Diabetes Care.

[15]  Jooil Kim,et al.  Food-Effect Bioavailability and Fed Bioequivalence Studies , 2005 .

[16]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[17]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[18]  S. Griffen,et al.  Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. , 2016, Clinical therapeutics.